Every 8-K that CTS Corporation (CTS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CTS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CTS filings page.
CTS Corporation provides an investor update highlighting recent performance and outlook. For the twelve months ended June 2026, revenue was $564.3 million, with adjusted gross margin of 39.8%, adjusted EBITDA of $135.5 million and an adjusted EBITDA margin of 24.0%. Adjusted net earnings were $74.3 million, or $2.58 per diluted share.
Diversified markets contributed 58% of revenue, up from 35% in 2017, with last‑twelve‑months sales of $150 million in industrial (up 17% year over year), $99 million in medical (up 34% year over year) and $81 million in aerospace and defense (up 1% year over year). Transportation generated $234 million of LTM revenue, down 2% year over year but largely powertrain‑agnostic.
Updated 2026 guidance calls for revenue of $565–$585 million and adjusted diluted EPS of $2.55–$2.70. The company reports free cash flow of $86.4 million for 2025, has returned $314 million to shareholders since 2013, and targets 10% long‑term annual revenue growth supported by organic initiatives and strategic acquisitions.
CTS Corporation reported second-quarter 2026 net sales of $144.8 million, up 7% year over year. Sales to diversified end markets grew 15% and now represent 59% of revenue, while transportation sales decreased 2%, reflecting the company’s ongoing diversification strategy.
Net earnings were $19.2 million, a 13.2% margin, compared with $18.5 million (13.7%) a year earlier, and diluted EPS was $0.66 versus $0.62. Profitability improved more sharply on a non-GAAP basis: adjusted gross margin reached 41.5% (up 270 bps), adjusted EBITDA margin was 25.4% (up 240 bps), and adjusted diluted EPS was $0.74, up $0.17 from $0.57.
Operating cash flow was $33.4 million, generating free cash flow of $28.8 million. Book-to-bill ratio was 1.1 overall, including 1.17 in diversified markets, and transportation total booked business was $1.2b with $163m in new wins. CTS raised 2026 sales guidance to $565–$585 million and adjusted diluted EPS guidance to $2.55–$2.70, assuming current market conditions and an effective tax rate of 21–23% excluding discrete items.
CTS Corporation is changing its top leadership. Effective July 6, 2026, current President and CEO Kieran O’Sullivan will step down as CEO and become Executive Chairman, while Pratik Trivedi, currently Chief Operating Officer, will become President and CEO and join the Board, increasing its size from eight to nine directors.
Mr. Trivedi’s compensation as CEO includes base salary of $675,000 per year, a target annual cash bonus equal to 100% of salary for the 2026 fiscal year (prorated), and a new long-term equity award valued at $2,150,000, split 60% into performance-based restricted stock units and 40% into service-based restricted stock units. He is also expected to enter a change in control Severance Agreement providing double-trigger severance of up to two times salary and bonus plus an additional one times amount for non-compete obligations, along with continued benefits and up to $30,000 in outplacement services if triggered.
As Executive Chairman, Mr. O’Sullivan will receive base salary of $625,000 and a target annual cash bonus of 100% of salary for 2026, with no new long-term incentive award. His existing equity awards and change in control agreement remain in place under current terms.
CTS Corporation reported the results of its Annual Meeting of Shareholders held on May 14, 2026. Shareholders elected all eight director nominees, each receiving over 24.6 million votes in favor with relatively few votes against or abstentions and broker non-votes recorded.
Shareholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 25,021,506 votes for, 655,182 against, 16,750 abstentions, and 825,870 broker non-votes. In addition, they ratified the appointment of Grant Thornton LLP as independent registered public accounting firm for the year ending December 31, 2026, by 25,989,929 votes for, 522,284 against, and 7,095 abstentions.
CTS Corporation furnished an investor presentation outlining its strategy, end‑market mix, and updated financial framework. Last twelve months revenue was $555 million with diversified markets representing 58% of revenue and transportation 42%. LTM adjusted EBITDA margin was 23% and LTM adjusted diluted EPS was $2.41.
For full‑year 2026, CTS targets revenue of $560–$580 million and adjusted diluted EPS of $2.35–$2.45, assuming slightly lower light‑vehicle production and continued growth in diversified end markets. The company highlights strong free cash flow, disciplined M&A, and a capital allocation framework that has returned $310 million to shareholders since 2013.
CTS Corporation reported strong first quarter 2026 results, with revenue of $139.2 million, up 11% year over year. Diversified end‑market sales grew 18%, while transportation revenue increased 3%, supporting a more balanced business mix.
Net earnings were $17.2 million, and diluted EPS rose to $0.59 from $0.44. Adjusted diluted EPS was $0.62, up from $0.44, as adjusted gross margin improved to 39.5% and adjusted EBITDA margin reached 23.0%. CTS narrowed its 2026 guidance, now expecting sales of $560–$580 million and adjusted diluted EPS of $2.35–$2.45.
CTS Corporation furnished an investor presentation outlining recent performance, strategy, and 2026 guidance. For the twelve months ended December 2025, revenue was $541.3 million with adjusted EBITDA margin of 22.8% and adjusted diluted EPS of $2.23.
The business is increasingly diversified: industrial revenue was $140 million (up 12% year over year), medical revenue $85 million (up 21%), and aerospace & defense revenue $83 million (up 20%), while transportation revenue was $234 million (down 7%). Diversified end markets now represent 57% of revenue.
CTS reported free cash flow of $86.4 million in 2025 and has returned about $300 million to shareholders since 2013 through dividends and repurchases. For 2026, the company targets revenue of $550–$580 million and adjusted diluted EPS of $2.30–$2.45, supported by secular trends in automation, healthcare innovation, and electrification.
CTS Corporation reported stronger results for the fourth quarter and full year 2025, driven by growth in diversified industrial, medical, and aerospace & defense markets and better profitability. Fourth-quarter sales were $137.3 million, up 9% year over year, with diversified end markets up 16% and transportation down 1%. Net earnings rose to $19.7 million, and diluted EPS increased to $0.67 from $0.38, helped by higher gross and EBITDA margins.
For full-year 2025, sales reached $541.3 million, up 5%, while net earnings grew to $65.3 million and diluted EPS to $2.19 from $1.80. Diversified end markets grew 16% and represented 57% of revenue, partially offsetting a 7% decline in transportation revenue. Adjusted gross margin improved to 38.5% and adjusted EBITDA margin to 22.8%. Operating cash flow was $102.1 million and free cash flow $86.4 million, supporting $62 million returned to shareholders in 2025.
For 2026, CTS guides revenue of $550–$580 million and adjusted diluted EPS of $2.30–$2.45, assuming continued growth in diversified markets and softness in commercial-vehicle-related sales, with an expected tax rate of 21–23% excluding discrete items.
CTS Corporation reported a leadership change in its senior management team. On November 21, 2025, Martin Baumeister notified the company that he will resign from his role as Senior Vice President, effective at the close of business on December 5, 2025. The company states that his resignation is a personal decision to pursue another opportunity outside CTS and is not due to any disagreement with the company.
Effective the same date, December 5, 2025, CTS has appointed Pratik Trivedi, currently a Senior Vice President, as its new Chief Operating Officer. Trivedi, age 46, joined CTS in April 2024 and previously held leadership roles at Eaton Corporation plc and Cummins, Inc. CTS states that it did not enter into any material new plan or contract, nor did it change his compensation or grant equity in connection with this COO appointment.
CTS Corporation entered into a new five-year unsecured Credit Agreement providing a $300 million revolving credit facility with a bank syndicate led by Wells Fargo. The new facility replaces the company’s prior $400 million unsecured credit facility, which was terminated on November 24, 2025, after using initial borrowings to repay $63.3 million outstanding under the prior agreement.
The facility includes $20 million swing line and letter of credit sublimits and a $150 million alternative currency sublimit. Interest rates vary by loan type and are based on benchmark rates plus a margin tied to CTS’s net leverage ratio, and a quarterly commitment fee applies to unused capacity. Key covenants require a net leverage ratio not greater than 3.5 to 1.0, with a temporary step-up to 4.25 to 1.0 allowed around certain large acquisitions, and an interest coverage ratio of at least 3.0 to 1.
CTS Corporation expanded its Board of Directors from seven to eight members and elected Kimberly MacKay to fill the new seat, effective November 5, 2025. MacKay serves as SVP, General Counsel and Corporate Secretary of West Pharmaceutical Services and will join CTS’s Nominating, Governance and Sustainability Committee and Technology and Transactions Committee.
As a non-employee director, she will receive compensation consistent with other non-employee directors as described in the Company’s March 28, 2025 proxy statement. The Company reported no arrangements leading to her selection and no related person transactions requiring disclosure under Item 404(a). CTS will enter into its standard indemnification agreement with her, and a related press release was furnished as Exhibit 99.1 on November 6, 2025.
CTS Corporation furnished an investor presentation under Item 7.01 (Regulation FD) in a Form 8‑K. The presentation, included as Exhibit 99.1 and dated October 2025, may be used in meetings with investors and analysts during the fiscal year ended December 31, 2025. The company states the materials are furnished, not filed, and are not subject to Section 18 liability or incorporated by reference unless specifically referenced.
CTS Corporation furnished an update on its business by providing a press release with certain results for the third quarter ended September 30, 2025, and related presentation materials. The company also announced a live webcast on October 28, 2025 to discuss these results.
The materials are furnished under Items 2.02 and 7.01 and are not deemed filed under the Exchange Act. Attached exhibits include the earnings release (Exhibit 99.1), the Q3 2025 slide deck (Exhibit 99.2), and the cover page interactive data file (Exhibit 104).
CTS Corporation filed a Form 8-K dated 24 July 2025 under Item 7.01 (Reg FD). The filing furnishes, but does not file, an investor presentation (Exhibit 99.1) that may be used in meetings with investors and analysts during fiscal-year 2025. Management explicitly disclaims that the furnished material should be deemed “filed” for Exchange Act liability or incorporated by reference into other SEC filings. No financial results, transaction details, or strategic announcements are included. Exhibit 104 covers the Inline XBRL cover-page data.
CTS Corporation (NYSE: CTS) filed an 8-K on July 1, 2025 announcing the appointment of Mark Pacioni, age 59, as Chief Legal & Administrative Officer and Corporate Secretary, effective immediately.
Professional background: Pacioni brings more than 30 years of legal experience, most recently serving as Chief Legal Officer and Secretary of CareerBuilder + Monster (2019-2025). Earlier roles include senior legal positions at Knowles Corp., Molex, Boeing, private practice focused on public-company transactions, and a tenure as Special Counsel at the U.S. SEC. He holds both a J.D. and B.A. from Georgetown University.
Compensation package:
- Base salary: $375,000
- Target annual incentive: 55 % of base salary
- Equity grants: 4,600 time-based RSUs (3-year vesting) and 7,000 performance-based RSUs (3-year performance period tied to financial metrics)
- Eligibility for the Company’s standard executive benefit plans
The Company simultaneously issued a press release (Exhibit 99.1) to announce the appointment. No other items, financial results, or transactions were disclosed in this filing.